The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Baricitinib Has Promising Clinical Trial Results for Treating RA

Baricitinib Has Promising Clinical Trial Results for Treating RA

May 18, 2016 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270Baricitinib is a preferential JAK1 and JAK2 inhibitor that has completed Phase 2 clinical trials, the results of which were published in 2015.

You Might Also Like
  • Osteoarthritis Treatments: Monoclonal Antibody Starts Clinical Trial & Fasinumab Promising for Treating Pain
  • Baricitinib May Exhibit Better Efficacy Than Adalimumab for RA
  • Baricitinib Effective for Treating Refractory Rheumatoid Arthritis
Also By This Author
  • OA Knee Pain Treatment Enters Clinical Trials, Ixekizumab Receives FDA Approval & Belimumab Promising for SLE Patients

In a recent Phase 3 study, baricitnib was used to treat patients with rheumatoid arthritis (RA) who had an inadequate response to or unacceptable side effects from more than one tumor necrosis factor inhibitor or other biologic disease-modifying anti-rheumatic drug (DMARD).1 This study was the RA-BEACON trial, which was a randomized, 24-week, double-blind, placebo-controlled study in 24 countries and 178 centers.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Participants were randomized to receive 2 mg baricitinib daily, 4 mg baricitinib daily or placebo. Continued treatment with stable doses of conventional synthetic DMARDs, NSAIDs, analgesics, glucocorticoids (≤10 mg prednisone or equivalent) or a combination of these agents was allowed. At Weeks 14 and 16, patients with less than a 20% improvement in tender and swollen joints were given 4 mg baricitinib daily as a rescue medication. After Week 16, rescue medication was allowed at the investigators’ discretion. Patients completing the study could enter a long-term extension study or be evaluated 28 days later for follow-up. The primary endpoint was the achievement of ACR20 at Week 12; secondary endpoints included: the Health Assessment Questionnaire–Disability Index (HAQ-DI) score with a change from baseline, the 28-joint Disease Activity Score based on C-reactive protein level (DAS28-CRP) with a change from baseline and a Simplified Disease Activity Index (SDAI) score of <3.3 (on a scale of 0.1 to 86.0; a score of <3.3 indicates remission).

Five hundred and twenty-seven patients were randomized into groups with a 1:1:1 ratio. In the group treated with 4 mg baricitinib, significantly more patients achieved ACR20 compared with placebo (55% baricitinib vs. 27% placebo, P<0.001). The 4 mg baricitinib-treated patients also had significant responses for the HAQ-DI score and the DAS-28-CRP, but not for the SDAI <3.3. Of enrolled patients, 40–46% had received at least one previous biologic, 27–33% had received at least two biologics, and 25–29% of patients had received at least three biologic agents.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

More patients treated with baricitinib compared with placebo experienced adverse events. Patients treated with 4 mg baricitinib had more infections (71–77% vs. 64% placebo), as well as those treated with 2 mg baricitinib (40–44% vs. 31% placebo). Serious adverse events occurred in 4% of 2 mg baricitinib-treated patients, 10% of 4 mg baricitinib-treated patients and 7% of placebo-treated patients. In the 4 mg baricitinib-treated group, two participants had nonmelanoma skin cancers, and two had major cardiovascular events, including a fatal stroke. Small reductions in neutrophil counts, small increases in serum creatinine and small increases in low-density lipoprotein levels occurred with baricitinib.

This study showed that in patients with RA who were previously unresponsive to biologic DMARDs, TNF inhibitors and other agents, a daily dose of 4 mg baricitinib led to clinical improvements at Week 12. This agent may prove beneficial in severe RA for whom many treatments have already been tried.


Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016 Mar 13;374(13):1243–1252. doi: 10.1056/NEJMoa1507247.

Pages: 1 2 | Multi-Page

Filed Under: Biologics & Biosimilars, Drug Updates, Rheumatoid Arthritis Tagged With: baricitinib, clinical trial, JAK inhibitors, Rheumatoid Arthritis (RA)

You Might Also Like:
  • Osteoarthritis Treatments: Monoclonal Antibody Starts Clinical Trial & Fasinumab Promising for Treating Pain
  • Baricitinib May Exhibit Better Efficacy Than Adalimumab for RA
  • Baricitinib Effective for Treating Refractory Rheumatoid Arthritis
  • Clinical Trials: Zilretta Promising for Knee OA Pain & Golimumab Completes Phase 3 Trial

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)